Document is current
Any future updates will be listed below
-
Authors
Roquelaure, Bertrand
Sciveres, Marco
Grammatikopoulos, Tassos
Lurz, Eberhard
Freudenberg, Folke
Habes, Dalila
Thevathasan, Lionel
Elaraki, Fatine
Gonzales, Emmanuel https://orcid.org/0000-0002-1546-3193
- License Information
-
More Information
Article History
Received: 6 February 2025
Accepted: 9 April 2025
First Online: 12 May 2025
Declarations
:
: Written consent to participate in the clinical trial or the compassionate use programme was obtained from the parents of all participating children before administration of odevixibat. The protocols of both the clinical trial and the compassionate use programme were submitted to and approved by the relevant institutional review boards or ethics committees in each country.
: Not applicable.
: EG is a consultant at Albireo/Ipsen, Theravia, Mirum, and Vivet; and advisory board member at Ipsen and Mirum. TG has received consultancy fees from Albireo/Ipsen. MS declares consultancy fees from Albireo/Ipsen and Mirum. At the time of this study, LT and FE were employees of Albireo Pharma Inc, who developed odevixibat, and FE is a current employee of Ipsen, the current marketing authorisation holder. BR, EL, FF, DH declare no conflicts of interest to disclose.
